
A meta-analysis of 52 RCTs (n=4734) revealed that GLP-1 RAs significantly lower inflammation biomarkers (CRP, TNF-α, IL-6, IL-1β, leptin) and increase adiponectin in type 2 diabetes patients. Compared to placebo or conventional therapy, GLP-1 RAs demonstrated consistent benefits over a median 24-week follow-up. These findings highlight the dual glycemic and anti-inflammatory potential of GLP-1 RAs in T2DM management.
Like
Save
Share